Bruker Corporation · NASDAQ:BRKR
Bruker — 40th Annual J.P. Morgan Healthcare Conference 2022
26 slides from Bruker's conference presentation, Jan 10, 2022
Slide 1: Bruker Corporation 2022 JP Morgan Healthcare Conference
IN N OVATION WITH IN TEG RIT Y Bruker Corporation (Nasdaq: BRKR) 2022 JP Morgan Healthcare Conference Frank Laukien, Chairman, President & CEO January 10, 2022
Slide 2: Safe Harbor Statement
BRUKER CORPORATION Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
Slide 3: Preliminary Q4 and FY 2021 Revenue
BRUKER PRELIMINARY Q4 AND FY 2021 REVENUE Preliminary Q4-21 Revenue Range Above Expectations Capping off a Strong Growth Year 2021 Preliminary Q4 and FY 2021 Revenue YTD Q3 2021 Financials (YoY) Current expectations: ❖ Revenue increased $374.4M, or +27.5% ❖ Q4 2021 revenue estimate of $665 - $670 mi
Slide 4: Revenue Growth, Margin Expansion and EPS
BRUKER CORPORATION Revenue Growth, Margin Expansion and EPS A solid track record of growth - with exceptional improvements in LTM 9/30/21(1) REVENUE ($B) NON-GAAP (2) OPERATING MARGIN NON-GAAP (2) EPS 330 150 90 90 80 19% 34% 2% 16% 12% 2.0% (2.3%) 3.6% 4.3% 5.7% PROJECT ACCELERATE 2.0 OPERATIONAL E
Slide 5: Premier Provider of High-Performance Scientific Instruments and Life Science Solutions
Premier Provider of High-Performance Scientific Instruments, and Life Science Research & Diagnostic Solutions Differentiated. Innovative. Entrepreneurial. ▪ Long track record of technological innovation ▪ Culture of disciplined entrepreneurialism ▪ Extensive collaborations with renowned science labs
Slide 6: Our Strategy Focuses on Accelerating Revenue Growth While Delivering Margin Expansion
DUAL STRATEGY Our Strategy Focuses on Accelerating Revenue Growth While Continuing to Deliver Sustainable Margin Expansion Project Accelerate 2.0(1) Operational Excellence ▪ Innovation & growth ▪ Commercial excellence ▪ Significant margin expansion ▪ Product R&D excellence ▪ Expanding margins ▪ Expa
Slide 7: Operational Excellence
DUAL STRATEGY – PROJECT ACCELERATE & OPERATIONAL EXCELLENCE Operational Excellence ▪ Driving innovation, growth, productivity and margins ▪ 2020-2021 CAPEX investments ~$100M p.a. for R&D, productivity and capacity Expanded Bruker Ettlingen facility, now with consolidated Bruker Nano Penang Facility
Slide 8: Microbiology & Molecular DX: Robust Microbiology Business Growth
PROJECT ACCELERATE 2.0 UPDATES Microbiology & Molecular DX: Robust Microbiology Business Growth MALDI Biotyper at accelerated DD revenue growth yoy in 2021 ▪ FY2021: >50% yoy U.S. order growth aided by Sepsityper FDA clearance in Dec. 2020 ▪ >600 MBT units sold in 2021 globally Sepsis: When every ho
Slide 9: NSF-Funded Network for Advanced NMR Orders Two 1.1 GHz NMRs
PROJECT ACCELERATE 2.0 UPDATES NSF-Funded Network for Advanced NMR Orders Two 1.1 GHz NMRs NAN consortium to operate with ‘hub and spoke’ model to meet evolving scientific and disease biology needs ❖ University of Connecticut hub facilitating access to NMR instrumentation, experimental protocols and
Slide 10: BioPharma: Multiple Solutions Leading to Rapid Growth
PROJECT ACCELERATE 2.0 UPDATES BioPharma: Multiple Solutions Leading to Rapid Growth ▪ Highly differentiated NMR, MS and FTIR/NIR solutions for drug discovery, binding assays, drug development, reaction monitoring, and process analytical technologies for small molecule drugs and biologics ▪ Market l
Slide 11: Benchtop Fourier 80 FT-NMR
PROJECT ACCELERATE 2.0 UPDATES Benchtop FourierTM 80 FT-NMR ❖ Fourier 80 benchtop system enables FT-NMR without cost, space, cryogens or expertise for superconducting high-field NMR ❖ Product innovations in 2021: ✓ Gradient spectroscopy standard for throughput and better results ✓ Industry-leading a
Slide 12: timsTOF 4D-Proteomics
BREAKOUT OPPORTUNITY - 4D PROTEOMICS timsTOF® 4D-Proteomics™ timsTOF Installed Base Large-cohort plasma ▪ timsTOF platform installed base >425 proteomics, PTMs >425 units at end of 2021 >300 Tissue & cell culture ▪ timsTOF revenue growth >30% yoy proteomics, PTMs to >$100M in FY2021 2020 2021 Biopha
Slide 13: Ultra-high sensitivity timsTOF SCP for single-cell proteomics
BREAKOUT OPPORTUNITY - 4D PROTEOMICS Ultra-high sensitivity timsTOF SCP for unbiased, deep single-cell proteomics ▪ Perfectly complements scRNA-seq ▪ 3,500 proteins, 25k peptides at 5ng loaded ▪ Mann et al. SCP publication: ~1,500 protein groups quantified in single cells after laser capture microdi
Slide 14: Leveraging Fluorescence Imaging Technology for Spatial Biology and Cellular Analysis
BREAKOUT OPPORTUNITY - SPATIAL BIOLOGY Leveraging Our Fluorescence Imaging Technology for Spatial Biology and Cellular Analysis Bulk/Ensemble Single-Cell Spatial Analysis Methods Methods Methods 3 platforms for spatial in situ o Canopy Biosciences ChipCytometry PROTEOMICS for high plex targeted spat
Slide 15: Canopy Launches Targeted Proteomics Kits for ChipCytometry
BREAKOUT OPPORTUNITY - SPATIAL BIOLOGY Canopy Launches Targeted Proteomics Kits for ChipCytometryTM ❖ Canopy assay kits are validated and optimized for Canopy ZellScannerONE instrument to quantitatively image dozens of targeted protein biomarkers simultaneously on a single tissue section at single-c
Slide 16: Acquisition of MOLECUBES Strengthens NMI for Preclinical Imaging
NUCLEAR MOLECULAR IMAGING (NMI) ACQUISITION Acquisition of MOLECUBES Strengthens NMI for Preclinical Imaging MOLECUBES is a dynamic innovator in benchtop preclinical NMI systems Modular benchtop CUBES™ NMI systems of MOLECUBES ▪ PET, SPECT, and CT CUBES™, with global installed base of >70 systems ▪
Slide 17: Recent Investments and Financial Developments
BRUKER CORPORATION Recent Investments and Financial Developments Invest Maintain Return in Growing the Business Financial Flexibility Capital to Shareholders • R&D investments of 9-10% of revenue p.a. • ~$500M Private Placement in Dec. • Planned annual dividend increase to • CAPEX investments ~$100M
Slide 18: Bruker Building Momentum - Setting Up for a Solid 2022
BRUKER CORPORATION Bruker Building Momentum - Setting Up for a Solid 2022 timsTOF® Spatial Biology & MALDI Biotyper & NMR Functional Unique Biopharma Semi Metrology & 4D-Proteomics Single-Cell Omics LiquidArray Panels Structural Biology Solutions for Biologics Microelectronics Microbiology & MDx Uni
Slide 19: Appendix
Appendix 19
Slide 20: Faster Growth from Six Expanded High-Growth, High-Margin Initiatives
PROJECT ACCELERATE 2.0 Faster Growth from Six Expanded High-Growth, High-Margin Initiatives Unbiased 4D-Proteomics & Unbiased Epiproteomics, Functional Consumables, Scientific Proteomics & Structural Biology, SCP Software & Aftermarket Multiomics Proteomics, PTMs, multiomic Consumables, assays, serv
Slide 21: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
BRUKER CORPORATION Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, 2016 (1) 2017 (1) 2018 2019 2020 2020 2
Slide 22: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
BRUKER CORPORATION Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, (1) 2016 2017 (1) 2018 2019 2020 2020 2
Slide 23: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
BRUKER CORPORATION Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, 2016 (1) 2017 (1) 2018 2019 2020 2020 2
Slide 24: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
BRUKER CORPORATION Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, (1) 2016 2017 (1) 2018 2019 2020 2020 2
Slide 25: YTD Q3 2021 Reconciliation of GAAP Revenue Growth to Organic Revenue Growth
BRUKER CORPORATION YTD Q3 2021 Reconciliation of GAAP Revenue Growth to Organic Revenue Growth (Unaudited) Nine Months Ended (in millions) September 30, 2021 Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth Total Bruker GAAP Revenue as of Prior Comparable Period $ 1,360.0 Non
Slide 26: ;
;
Bruker — 40th Annual J.P. Morgan Healthcare Conference 2022 on 6ix